Spinal Muscular Atrophy

🧠 Standard of Care & Symptoms

Spinal Muscular Atrophy (SMA) is a progressive, autosomal recessive neuromuscular disease characterized by degeneration of lower motor neurons in the anterior horn of the spinal cord, leading to progressive muscle weakness and atrophy.

• Clinical Types & Severity:
  • SMA Type 1 (Werdnig-Hoffmann Disease): Severe, infantile-onset (onset < 6 months). Infants present with marked hypotonia ("floppy infant" phenotype), difficulty feeding and breathing, and never achieve the ability to sit. Historically fatal before age 2 without mechanical ventilation.
  • SMA Type 2 (Intermediate SMA): Onset between 6 and 18 months. Children can sit independently but cannot stand or walk without assistance. Tremors of the hands are common.
  • SMA Type 3 (Kugelberg-Welander Disease): Mild, juvenile-onset (onset > 18 months). Patients achieve independent walking but may lose this ability as the disease slowly progresses.
• Pathophysiology: Caused by homozygous deletion or loss-of-function mutations in the **SMN1 gene** on chromosome 5q, which encodes the survival motor neuron (SMN) protein. The **SMN2 gene** is a nearly identical backup gene, but a splicing defect causes it to exclude exon 7 in ~90% of transcripts, producing a truncated, unstable SMN protein. The clinical severity of SMA is inversely related to the copy number of the **SMN2** gene.

🧬 Diagnostics & Genetic Parameters

Diagnosis requires molecular genetic analysis to evaluate deletions and copy number parameters.

• Genetic Testing (PCR / MLPA): The primary diagnostic test. Identifies the homozygous deletion of exon 7 in the *SMN1* gene (diagnostic in 95% of cases). Multiplex Ligation-dependent Probe Amplification (MLPA) is also utilized to quantify the **SMN2 copy number**, which guides prognosis and eligibility for immediate gene therapies.
• Newborn Screening (NBS): Universal newborn screening allows for the identification of infants with SMA before symptoms manifest, enabling treatment initiation within the first few weeks of life to preserve motor neuron function.

Molecular Splice Mechanics of SMN2

The differences between SMN1 and SMN2 lie in a single, critical nucleotide variation:

• The Splicing Defect: A single nucleotide transition (**C-to-T at position 6 of exon 7**) in SMN2 does not alter the encoded amino acid, but it disrupts an **Exonic Splicing Enhancer (ESE)** recognized by the splicing factor SF2/ASF. Simultaneously, it creates an **Exonic Splicing Silencer (ESS)**. This results in the frequent skipping of exon 7 during pre-mRNA splicing, producing a truncated, non-functional protein ($\Delta$7 SMN) that is rapidly degraded.
• Splicing Modification Target: Therapeutics like Nusinersen and Risdiplam work by binding to an **Intronic Splicing Silencer (ISS-N1)** located in intron 7 of the SMN2 pre-mRNA. By blocking this silencer site, these therapies prevent inhibitory splicing factors (like hnRNP A1) from binding, thereby forcing the inclusion of exon 7 and restoring production of functional, full-length SMN protein.

💊 Gene Therapy & Splicing Modifiers

The therapeutic landscape has been transformed by therapies that increase SMN protein levels in the central nervous system.

• Gene Transfer Therapy (Onasemnogene Abeparvovec / Zolgensma): An FDA-approved, single-dose intravenous infusion for pediatric patients under age 2. It utilizes a non-replicating adeno-associated virus 9 (AAV9) vector to deliver a functional copy of the human **SMN1 transgene** to motor neurons, initiating steady SMN protein synthesis.
• Antisense Oligonucleotides (Nusinersen / Spinraza): Administered via intrathecal (spinal) injection. Nusinersen binds to SMN2 pre-mRNA, modifying its splicing to force the inclusion of exon 7, resulting in the production of functional, full-length SMN protein.
• Oral Small Molecule Splicing Modifiers (Risdiplam / Evrysdi): A daily oral liquid medication that similarly targets SMN2 pre-mRNA splicing to promote exon 7 inclusion, distributing SMN protein throughout the body.
• Supportive Care: Proactive nutritional support (due to swallowing dysfunction), pulmonary care (assisted cough devices, non-invasive ventilation), and physical therapy to prevent contractures.

🔬 Active Clinical Trials

Clinical trials are currently evaluating muscle-directed combination therapies to enhance muscle contractility alongside SMN-enhancing therapies, next-generation gene delivery systems, and long-term safety studies.

🗺️ Next Steps After Diagnosis

If you or your child has recently been diagnosed with Spinal Muscular Atrophy, establish these immediate care pathways:

1. Coordinate SMN2 Copy Number Quantification: Verify that your genetic test report specifies the SMN2 copy number, as this dictates molecular eligibility for Zolgensma and other therapeutics.
2. Consult a Pediatric Neurologist Immediately: Time is motor neurons. Prompt therapeutic intervention (often within weeks of birth for presymptomatic infants) is critical to prevent irreversible degeneration.
3. Contact a Multidisciplinary SMA Care Center: Comprehensive care requires a team including pulmonology, nutrition, physical therapy, and orthopedic specialists.
4. Perform baseline liver and cardiac testing: If planning gene transfer therapy, obtain baseline liver function tests and AAV9 antibody titers.

❓ Patient FAQ

Q: Why is early treatment so critical in spinal muscular atrophy?
A: Motor neurons degenerate rapidly in the absence of the SMN protein. Once motor neurons are lost, they cannot be regenerated. Initiating therapy presymptomatically or immediately after symptom onset halts this loss, allowing children to achieve near-normal motor milestones.

Q: What is the significance of the SMN2 copy number?
A: While SMN2 primarily produces truncated protein, a small percentage of full-length protein is produced. Patients with more copies of the SMN2 gene (e.g. 3 or 4 copies) produce more functional SMN protein and exhibit a milder phenotype (SMA Type 2 or 3) than those with only 2 copies (SMA Type 1).